Race to stop the world getting sick: As coronavirus ravages the globe, experts work around the clock developing vaccines and trialling drugs in a desperate attempt to contain it

by Pat Hagan, Daily Mail As the needle slipped into Jennifer Haller’s arm, the world watched and held its breath. This was the moment last week when Jennifer became the first person to be injected with an experimental vaccine that scientists hope will help prevent future pandemics of the deadly Covid-19 coronavirus. Mother-of-two Jennifer, 43, […]

Wanted: People Willing to Get Sick to Find Coronavirus Vaccine

British lab is recruiting volunteers for study it says could speed development of Covid-19 vaccine By Denise Roland March 19, 2020 7:00 am ET Thousands of people have volunteered to be infected in the hope of finding a vaccine for the new coronavirus. hVIVO, a clinical research group in London, has attracted more than 20,000 […]

Open Orphan #ORPH – Publication of positive FLU-v vaccine challenge study results in journal

Positive results from FLU-v vaccine challenge study (FLU-v 004), the second Phase IIb study of FLU-v, which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group, have now been published in a peer review journal FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate The publication in ‘npj Vaccines’ […]

Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study

Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal. The data from the FLU-v 003 […]

Open Orphan #ORPH – Publication of Positive Results in Journal

Positive results from Phase IIb field study of FLU-v vaccine (FLU-v 003), which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group. FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate and the results have now been published in a peer review journal The publication in the Annals […]

Open Orphan #ORPH – Completion of the compulsory acquisition of remaining hVIVO shares

Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, announces that further to the announcement of 28 January 2020, the Company will shortly be posting letters to shareholders of hVIVO plc […]

Open Orphan #ORPH – Development of the World’s First Human Coronavirus Challenge Study Model

Open Orphan, the rapidly growing specialist Clinical Research Organisation (“CRO”) pharmaceutical services company whose London-based subsidiary hVIVO is the world leader in the provision of virology and vaccine challenge study services, is pleased to announce that it has commenced the development of the world’s first commercial human coronavirus challenge study model, also known as a Controlled […]